Austria-Graz: Research and experimental development services
2021/S 204-533482

Contract notice

Services

Legal Basis:
Directive 2014/24/EU

Section I: Contracting authority

I.1) **Name and addresses**

Official name: Medizinische Universität Graz (MUG)
Postal address: Auenbruggerplatz 2
Town: Graz
NUTS code: AT221 Graz
Postal code: 8036
Country: Austria
Contact person: Kurt Zatloukal
E-mail: kurt.zatloukal@medunigraz.at
Internet address(es):
Main address: www.medunigraz.at

I.1) **Name and addresses**

Official name: Universita Degli Studi di Firenze (UNIFI)
Postal address: Piazza S.Marco, 4
Town: Firenze
NUTS code: ITI14 Firenze
Postal code: 50121
Country: Italy
Contact person: Pamela Pinzani
E-mail: pamela.pinzani@unifi.it
Internet address(es):
Main address: www.unifi.it

I.1) **Name and addresses**

Official name: Erasmus Universitair Medisch Centrum Rotterdam (EMC)
Postal address: Dr. Molewaterplein 40
Town: GD Rotterdam
NUTS code: NL33C Groot-Rijnmond
Postal code: 3015
Country: Netherlands
Contact person: Peter Riegman
E-mail: p.riegman@erasmusmc.nl
Internet address(es):
Main address: www.erasmusmc.nl

I.1) **Name and addresses**

Official name: St. Anna Kinderkrebsforschung GmbH (CCRI GmbH)
Postal address: Zimmermannplatz 10
Town: Vienna
NUTS code: AT130 Wien
Postal code: 1090
Country: Austria
Contact person: Joao Frade
E-mail: joao.frade@ccri.at
Internet address(es):
Main address: www.ccri.at

I.1) **Name and addresses**

Official name: Universita' Degli Studi di Milano-Bicocca (UNIMIB)
Postal address: Piazza dell'Ateneo Nuovo, 1
Town: Milano
NUTS code: ITC4C Milano
Postal code: 20126
Country: Italy
Contact person: Maria Luisa Lavitrano
E-mail: marialuisa.lavitrano@unimib.it
Internet address(es):
Main address: www.unimib.it

I.1) **Name and addresses**

Official name: University Clinic of Schleswig-Holstein (UKSH)
Postal address: Rosalind-Franklin-Straße 12
Town: Kiel
NUTS code: DEF02 Kiel, Kreisfreie Stadt
Postal code: 24105
Country: Germany
Contact person: Michael Forster
E-mail: m.forster@ikmb.uni-kiel.de
Internet address(es):
Main address: www.ikmb.uni-kiel.de

I.1) **Name and addresses**

Official name: Centre Leon Berard (CLB)
Postal address: 28 Rue Laennec
Town: Lyon
NUTS code: FRK26 Rhône
Postal code: 69008
Country: France
Contact person: Jean-Yves Blay
E-mail: jean-yves.blay@lyon.unicancer.fr
Internet address(es):
Main address: www.centreleonberard.fr

I.2) **Information about joint procurement**

The contract involves joint procurement
In the case of joint procurement involving different countries, state applicable national procurement law:

This pre-commercial procurement (PCP) is carried out by the Medical University of Graz, Austria who was appointed as lead procurer to coordinate and lead the joint procurement in the name and on behal

I.3) **Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at:
www.instandngs4p.eu
Additional information can be obtained from another address:
Official name: instand-tender@medunigraz.at
Postal address: Auenbruggerplatz 2
Town: Graz
NUTS code: AT221 Graz
Postal code: 8036
Country: Austria
Contact person: Kurt Zatloukal
E-mail: instand-tender@medunigraz.at
Internet address(es):
Main address: www.instandngs4p.eu
Tenders or requests to participate must be submitted to the abovementioned address

I.4) **Type of the contracting authority**

Body governed by public law

I.5) **Main activity**

Health

Section II: Object

II.1) **Scope of the procurement**

II.1.1) **Title:**

Pre-commercial procurement to buy R&D services to develop fully integrated and standardized NGS workflows for routine diagnosis of common and rare cancers from adults and children
Reference number: 874719

II.1.2) **Main CPV code**

73100000 Research and experimental development services

II.1.3) **Type of contract**

Services

II.1.4) **Short description:**

This contract notice invites interested operators to submit tenders to a procurement.
The procurement aims to trigger new solutions to be developed and tested to address the following challenge: Development of two fully integrated and standardized NGS workflows, from sample-pre-analytics to medical decision making, for routine diagnostics of common and rare cancers from adults and children.
As the common challenge consists of a number of sub-challenges, the procurement will be divided into the following Lots, each corresponding to one sub-challenge:
— Lot 1: Pre-sequencing (Specimen collection, nucleic acid isolation, library preparation),
— Lot 2: Sequencing,
— Lot 3: Bioinformatics analysis,
— Lot 4: Integrated reporting.
This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).

II.1.5) **Estimated total value**

Value excluding VAT: 8 554 099.75 EUR

II.1.6) **Information about lots**

This contract is divided into lots: yes
Tenders may be submitted for maximum number of lots: 3
Maximum number of lots that may be awarded to one tenderer: 3

II.2) **Description**

II.2.1) **Title:**

Pre-sequencing (Specimen collection, nucleic acid isolation, library preparation)
Lot No: 1

II.2.2) **Additional CPV code(s)**

73100000 Research and experimental development services

II.2.3) **Place of performance**

NUTS code: AT221 Graz
Main site or place of performance:
Testing is expected to be done at the premises of the contractors using test material provided by the procurers and at a minimum of 3 and a maximum of 7 procurer sites.

II.2.4) **Description of the procurement:**

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.
Each selected operator will be awarded a framework agreement that covers 3 R&D phases.
The 3 phases are:
— solution design,
— prototyping,
— original development and testing of a limited set of first products or services.
Each of the 3 phases will address all 4 Lots. Each supplier can address more than one Lot, with a maximum of 3 Lots. A minimum of different suppliers addressing the same lot per phase is: 4 for phase 1, 3 for phase 2 and 2 for phase 3.
After each phase, intermediate evaluations will be carried out to progressively select the best of the competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the next phase. The phased approach with parallel contracts and intermediate evaluations will be followed within each Lot. The result of phase 3 will be the development of 2 fully integrated and standardized NGS workflows including quality control.
The procurement is expected to start in April 2022 (Phase 1) and end in May 2025 (end of Phase 3).
For Phase 2 prototype performance testing is expected to be done at the premises of the contractors using test material provided by the procurers. For Phase 3, the procurers will carry out the testing and verification of the solutions at their premises and optionally at another medical center in Romania. For Lot 2, solutions will be tested at 2 to 3 procurer sites. For Lots 1, 3 and 4, solutions will be tested at a minimum of 3 and a maximum of 7 procurer sites. This testing may also serve as a first customer test reference for the contractors.
The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions i.e. beyond the procurement.
This PCP will focus on developing 4 independent Lots, to be modularly integrated into two independent workflows, which could be e.g., target panel-based and/or whole genome / whole exome-based, for the

diagnosis and support of treatment decision making (including pharmacogenomics results generated by NGS) in common cancer entities and rare cancer entities.
The performance improvement which this PCP aims to develop, compared to the current state-of-the art technology, is the standardized integration of all steps of diagnostic NGS workflows from sample collection to reporting of results for decision making at the bed side. The analyses should include NGS data from tumour-derived specimens (including liquid biopsy) and data from pharmacogenomics analyses performed on non-tumour-derived specimens.
The main technical challenges and minimum requirements to be addressed are described in the Request for Tender (RfT) document, which, together with this Contract Notice, provides the binding information for preparation of the tender (RfT is available on the project website at www.instandngs4p.eu).
Each Lot contains a defined number of technical challenges that were identified by the Buyers and refined by the feedback received during the open market consultation (OMC) webinars and questionnaires. These technical challenges reflect the specific needs of the NGS workflow for use in medical diagnostics of potential users and establish a list of demands/requirements that the Suppliers should try to solve. It is not mandatory that a Supplier covers every issue mentioned under the technical challenges through a single application. The evaluation will take into account the number of challenges addressed and how well the solutions cover them based on the fulfilment minimal requirements and award criteria, described in the RfT, including the innovation level in addressing them.

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

Value excluding VAT: 1 708 889.00 EUR

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 37
This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:
This procurement receives funding from the European Union’s Horizon 2020 Research and Innovation Programme, under grant agreement No 874719 — INSTAND-NGS4P(see https:www.instandngs4p.eu).The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.

II.2.14) **Additional information**

Information on technical challenges and minimum lot requirements is available on the project website www.instandngs4p.eu and in the Request for Tender document.

II.2) **Description**

II.2.1) **Title:**

Sequencing
Lot No: 2

II.2.2) **Additional CPV code(s)**

73100000 Research and experimental development services

II.2.3) **Place of performance**

NUTS code: AT221 Graz

Main site or place of performance:

Testing is expected to be done at the premises of the contractors using test material provided by the procurers and at 2 to 3 procurer sites.

II.2.4) **Description of the procurement:**

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.

Each selected operator will be awarded a framework agreement that covers 3 R&D phases.

The 3 phases are:

— solution design,

— prototyping,

— original development and testing of a limited set of first products or services.

Each of the 3 phases will address all 4 Lots. Each supplier can address more than one Lot, with a maximum of 3 Lots. A minimum of different suppliers addressing the same lot per phase is: 4 for phase 1, 3 for phase 2 and 2 for phase 3.

After each phase, intermediate evaluations will be carried out to progressively select the best of the competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the next phase. The phased approach with parallel contracts and intermediate evaluations will be followed within each Lot. The result of phase 3 will be the development of 2 fully integrated and standardized NGS workflows including quality control.

The procurement is expected to start in April 2022 (Phase 1) and end in May 2025 (end of Phase 3).

For Phase 2 prototype performance testing is expected to be done at the premises of the contractors using test material provided by the procurers. For Phase 3, the procurers will carry out the testing and verification of the solutions at their premises and optionally at another medical center in Romania. For Lot 2, solutions will be tested at 2 to 3 procurer sites. For Lots 1, 3 and 4, solutions will be tested at a minimum of 3 and a maximum of 7 procurer sites. This testing may also serve as a first customer test reference for the contractors.

The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions i.e. beyond the procurement.

This PCP will focus on developing 4 independent Lots, to be modularly integrated into two independent workflows, which could be e.g., target panel-based and/or whole genome / whole exome-based, for the diagnosis and support of treatment decision making (including pharmacogenomics results generated by NGS) in common cancer entities and rare cancer entities.

The performance improvement which this PCP aims to develop, compared to the current state-of-the art technology, is the standardized integration of all steps of diagnostic NGS workflows from sample collection to reporting of results for decision making at the bed side. The analyses should include NGS data from tumour-derived specimens (including liquid biopsy) and data from pharmacogenomics analyses performed on non-tumour-derived specimens.

The main technical challenges and minimum requirements to be addressed are described in the Request for Tender (RfT) document, which, together with this Contract Notice, provides the binding information for preparation of the tender (RfT is available on the project website at www.instandngs4p.eu).

Each Lot contains a defined number of technical challenges that were identified by the Buyers and refined by the feedback received during the open market consultation (OMC) webinars and questionnaires. These technical challenges reflect the specific needs of the NGS workflow for use in medical diagnostics of potential

users and establish a list of demands/requirements that the Suppliers should try to solve. It is not mandatory that a Supplier covers every issue mentioned under the technical challenges through a single application. The evaluation will take into account the number of challenges addressed and how well the solutions cover them based on the fulfilment minimal requirements and award criteria, described in the RfT, including the innovation level in addressing them.

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

Value excluding VAT: 1 708 889.00 EUR

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 37
This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:
This procurement receives funding from the European Union's Horizon 2020 Research and Innovation Programme, under grant agreement No 874719 — INSTAND-NGS4P(see https:www.instandngs4p.eu).The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.

II.2.14) **Additional information**

Information on technical challenges and minimum lot requirements is available on the project website www.instandngs4p.eu and in the Request for Tender document.

II.2) **Description**

II.2.1) **Title:**

Bioinformatics analysis
Lot No: 3

II.2.2) **Additional CPV code(s)**

73100000 Research and experimental development services

II.2.3) **Place of performance**

NUTS code: AT221 Graz
Main site or place of performance:
Testing is expected to be done at the premises of the contractors using test material provided by the procurers and at a minimum of 3 and a maximum of 7 procurer sites.

II.2.4) **Description of the procurement:**

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.
Each selected operator will be awarded a framework agreement that covers 3 R&D phases.
The 3 phases are:
— solution design,
— prototyping,
— original development and testing of a limited set of first products or services.
Each of the 3 phases will address all 4 Lots. Each supplier can address more than one Lot, with a maximum of 3 Lots. A minimum of different suppliers addressing the same lot per phase is: 4 for phase 1, 3 for phase 2 and 2 for phase 3.
After each phase, intermediate evaluations will be carried out to progressively select the best of the competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the next phase. The phased approach with parallel contracts and intermediate evaluations will be followed within each Lot. The result of phase 3 will be the development of 2 fully integrated and standardized NGS workflows including quality control.
The procurement is expected to start in April 2022 (Phase 1) and end in May 2025 (end of Phase 3).
For Phase 2 prototype performance testing is expected to be done at the premises of the contractors using test material provided by the procurers. For Phase 3, the procurers will carry out the testing and verification of the solutions at their premises and optionally at another medical center in Romania. For Lot 2, solutions will be tested at 2 to 3 procurer sites. For Lots 1, 3 and 4, solutions will be tested at a minimum of 3 and a maximum of 7 procurer sites. This testing may also serve as a first customer test reference for the contractors.
The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions i.e. beyond the procurement.
This PCP will focus on developing 4 independent Lots, to be modularly integrated into two independent workflows, which could be e.g., target panel-based and/or whole genome / whole exome-based, for the diagnosis and support of treatment decision making (including pharmacogenomics results generated by NGS) in common cancer entities and rare cancer entities.
The performance improvement which this PCP aims to develop, compared to the current state-of-the art technology, is the standardized integration of all steps of diagnostic NGS workflows from sample collection to reporting of results for decision making at the bed side. The analyses should include NGS data from tumour-derived specimens (including liquid biopsy) and data from pharmacogenomics analyses performed on non-tumour-derived specimens.
The main technical challenges and minimum requirements to be addressed are described in the Request for Tender (RfT) document, which, together with this Contract Notice, provides the binding information for preparation of the tender (RfT is available on the project website at www.instandngs4p.eu).
Each Lot contains a defined number of technical challenges that were identified by the Buyers and refined by the feedback received during the open market consultation (OMC) webinars and questionnaires. These technical challenges reflect the specific needs of the NGS workflow for use in medical diagnostics of potential users and establish a list of demands/requirements that the Suppliers should try to solve. It is not mandatory that a Supplier covers every issue mentioned under the technical challenges through a single application. The evaluation will take into account the number of challenges addressed and how well the solutions cover them based on the fulfilment minimal requirements and award criteria, described in the RfT, including the innovation level in addressing them.

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

Value excluding VAT: 2 563 333.00 EUR

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 37
This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:
This procurement receives funding from the European Union's Horizon 2020 Research and Innovation Programme, under grant agreement No 874719 — INSTAND-NGS4P(see https:www.instandngs4p.eu).The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.

II.2.14) **Additional information**

Information on technical challenges and minimum lot requirements is available on the project website www.instandngs4p.eu and in the Request for Tender document.

II.2) **Description**

II.2.1) **Title:**

Integrated reporting
Lot No: 4

II.2.2) **Additional CPV code(s)**

73100000 Research and experimental development services

II.2.3) **Place of performance**

NUTS code: AT221 Graz
Main site or place of performance:
Testing is expected to be done at the premises of the contractors using test material provided by the procurers and at a minimum of 3 and a maximum of 7 procurer sites.

II.2.4) **Description of the procurement:**

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.
Each selected operator will be awarded a framework agreement that covers 3 R&D phases.
The 3 phases are:
— solution design,
— prototyping,
— original development and testing of a limited set of first products or services.
Each of the 3 phases will address all 4 Lots. Each supplier can address more than one Lot, with a maximum of 3 Lots. A minimum of different suppliers addressing the same lot per phase is: 4 for phase 1, 3 for phase 2 and 2 for phase 3.
After each phase, intermediate evaluations will be carried out to progressively select the best of the competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the

next phase. The phased approach with parallel contracts and intermediate evaluations will be followed within each Lot. The result of phase 3 will be the development of 2 fully integrated and standardized NGS workflows including quality control.
The procurement is expected to start in April 2022 (Phase 1) and end in May 2025 (end of Phase 3).
For Phase 2 prototype performance testing is expected to be done at the premises of the contractors using test material provided by the procurers. For Phase 3, the procurers will carry out the testing and verification of the solutions at their premises and optionally at another medical center in Romania. For Lot 2, solutions will be tested at 2 to 3 procurer sites. For Lots 1, 3 and 4, solutions will be tested at a minimum of 3 and a maximum of 7 procurer sites. This testing may also serve as a first customer test reference for the contractors.
The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions i.e. beyond the procurement.
This PCP will focus on developing 4 independent Lots, to be modularly integrated into two independent workflows, which could be e.g., target panel-based and/or whole genome / whole exome-based, for the diagnosis and support of treatment decision making (including pharmacogenomics results generated by NGS) in common cancer entities and rare cancer entities.
The performance improvement which this PCP aims to develop, compared to the current state-of-the art technology, is the standardized integration of all steps of diagnostic NGS workflows from sample collection to reporting of results for decision making at the bed side. The analyses should include NGS data from tumour-derived specimens (including liquid biopsy) and data from pharmacogenomics analyses performed on non-tumour-derived specimens.
The main technical challenges and minimum requirements to be addressed are described in the Request for Tender (RfT) document, which, together with this Contract Notice, provides the binding information for preparation of the tender (RfT is available on the project website at www.instandngs4p.eu).
Each Lot contains a defined number of technical challenges that were identified by the Buyers and refined by the feedback received during the open market consultation (OMC) webinars and questionnaires. These technical challenges reflect the specific needs of the NGS workflow for use in medical diagnostics of potential users and establish a list of demands/requirements that the Suppliers should try to solve. It is not mandatory that a Supplier covers every issue mentioned under the technical challenges through a single application. The evaluation will take into account the number of challenges addressed and how well the solutions cover them based on the fulfilment minimal requirements and award criteria, described in the RfT, including the innovation level in addressing them.

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

Value excluding VAT: 2 563 333.00 EUR

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 37
This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: yes

Identification of the project:
This procurement receives funding from the European Union's Horizon 2020 Research and Innovation Programme, under grant agreement No 874719 — INSTAND-NGS4P(see https:www.instandngs4p.eu).The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.

II.2.14) **Additional information**
Information on technical challenges and minimum lot requirements is available on the project website www.instandngs4p.eu and in the Request for Tender document.

Section III: Legal, economic, financial and technical information

III.1) **Conditions for participation**

III.1.2) **Economic and financial standing**
Selection criteria as stated in the procurement documents

III.1.3) **Technical and professional ability**
Selection criteria as stated in the procurement documents

III.2) **Conditions related to the contract**

III.2.3) **Information about staff responsible for the performance of the contract**
Obligation to indicate the names and professional qualifications of the staff assigned to performing the contract

Section IV: Procedure

IV.1) **Description**

IV.1.1) **Type of procedure**
Open procedure

IV.1.3) **Information about a framework agreement or a dynamic purchasing system**
The procurement involves the establishment of a framework agreement
Framework agreement with several operators
In the case of framework agreements, provide justification for any duration exceeding 4 years:
Following the tendering stage, a framework agreement and a specific contract for Phase 1 will be awarded to a minimum of 4 contractors per Lot. For Phase 2, a minimum of 3 contracts per Lot will be awarded and a minimum of 2 contracts per Lot will be awarded for Phase 3.

IV.1.8) **Information about the Government Procurement Agreement (GPA)**
The procurement is covered by the Government Procurement Agreement: no

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**
Notice number in the OJ S: 2020/S 252-636188

IV.2.2) **Time limit for receipt of tenders or requests to participate**
Date: 15/12/2021
Local time: 17:00

IV.2.3) **Estimated date of dispatch of invitations to tender or to participate to selected candidates**

IV.2.4) **Languages in which tenders or requests to participate may be submitted:**
English

IV.2.7) **Conditions for opening of tenders**
Date: 16/04/2022
Local time: 17:00

Section VI: Complementary information

VI.1) **Information about recurrence**

This is a recurrent procurement: no

VI.3) **Additional information:**

This PCP procurement are exempted from the EU public procurement directives and the national laws that implement them. (i.e. it is not an open and negotiated procedure subject to the EU public procurement directives; the choice here must be made for formal reasons only, because it is mandatory for filling out the form).

Participation in the open market consultation (OMC) that was held as part of the preparation for this procurement is not a prerequisite for submitting a tender.

This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs.

At least 50% of the total value of activities covered by the framework agreement (i.e. the total value of the activities covered by phase 1 + the total value of the activities covered by phase 2 + the total value of the activities covered by phase 3) must be performed in the EU Member States or H2020 associated countries. The key R&D staff working on the PCP must be located in the EU Member States or H2020 associated countries.

Publication of this contract notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation.

The open procedure was chosen in Section IV.1.1) 'Procedure' for formal reasons only. This is because it is not possible to publish a contract notice without selecting one of the listed procedures.

Offers shall be submitted in English. All communication (before, during and after the procurement) shall be in English.

More information:

See:

− A webinar dedicated to all the administrative, technical and financial aspects of this Tender will be held by the Lead procurer on November 3rd 2021 and instruction for the registration will be published on the Instand-NGS4P website.

− the project website (see www.instandngs4p.eu)

− the open market consultation and FAQs (see www.instandngs4p.eu)

− PCPs on the Europa website (see https://ec.europa.eu/digital-single-market/innovation-procurement)

or contact:

− instand-tender@medunigraz.at

VI.4) **Procedures for review**

VI.4.1) **Review body**

Official name: Federal Administrative Court in Graz
Postal address: Schlögelgasse 9
Town: Graz
Postal code: A-8010
Country: Austria
E-mail: einlaufstelle@bvwg.gv.at
Telephone: +43 1601490
Internet address: https://www.bvwg.gv.at/services/standorte/aussenstelle_graz.html

VI.4.2) **Body responsible for mediation procedures**

Official name: Competent Federal Civil Court in Graz
Postal address: Landesgericht für Zivilrechtssachen Marburger Kai 49
Town: Graz
Postal code: A-8010
Country: Austria

VI.4.3) **Review procedure**

Precise information on deadline(s) for review procedures:
The procurement is exempted from the EU public procurement directives (including the EU procurement remedies directives 89/665/EEC and 92/13/EEC — see above) and the national laws that implement them. Publication of this notice in the Official Journal is not to be understood as a waiver of this exemption by the contracting authority.
The deadlines for the review procedures at the bodies for review and mediation, mentioned in IV.4.1) and IV.4.2) are:
8 days after formal notification of the decision.

VI.5) **Date of dispatch of this notice:**

15/10/2021